The assumption makes sense on the surface: both are injectable GLP-1 medications, both are delivered under the skin, so the identical technique must work equally well for both
FDA-approved for type 2 diabetes treatment in 2017 and administered via a once-a-week injection, Semaglutide, have emerged as miracles for many individuals who've battled lifelong weight issues
A program that includes provider visits, lab work, nutritional guidance, and body composition monitoring may cost more upfront but typically delivers better safety and support than a low-cost, medication-only model
Consequently, this meta-analysis provides a more rigorous and clinically relevant evaluation of the relative therapeutic benefits of Semaglutide, Liraglutide, Dulaglutide, and Tirzepatide, facilitating a more evidence-based approach to treatment selection in the management of type 2 diabetes and obesity